Chronic heart failure is a progressive condition where the heart is unable to pump blood efficiently, leading to fatigue, breathlessness, and fluid buildup. Heart failure accounts for around 64 million cases globally, driving the demand for advanced therapies. The growing focus on innovative treatments, such as novel chronic heart failure drug candidates and personalized medicine, is reshaping the market. Factors like an aging population, increased R&D investment, and progress in gene and cell therapies are fueling growth. According to the chronic heart failure pipeline analysis by Expert Market Research, this evolving landscape of treatment options is expected to deliver significant advancements in the coming years, offering hope for better management and quality of life for the affected patients.
Report Coverage
The Chronic Heart Failure Pipeline Analysis Report by Expert Market Research gives comprehensive insights into chronic heart failure therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for chronic heart failure. The chronic heart failure report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The chronic heart failure pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with chronic heart failure treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to chronic heart failure.
Chronic Heart Failure Pipeline Outlook
Chronic heart failure is a long-term condition where the heart gradually loses its ability to pump blood efficiently. It occurs due to conditions like coronary artery disease, hypertension, or cardiomyopathy, which weaken or stiffen the heart muscle. Over time, this leads to fluid buildup, fatigue, and shortness of breath, significantly impacting a patient’s quality of life.
Chronic heart failure treatments focus on symptom management and disease progression control. Medications like beta-blockers, ACE inhibitors, and diuretics help improve heart function. Advanced therapies include chronic heart failure drug candidates, implantable devices, and heart transplants for severe cases. Emerging treatments, such as gene and cell therapy, offer hope for improved patient outcomes in the future. For instance, in July 2024, Zydus Lifesciences Ltd. received final United States Food and Drug Administration approval for its Sacubitril and Valsartan tablets, a novel treatment for chronic heart failure in adults. This combination therapy reduces the risk of death and hospitalization, marking a significant advancement in the heart failure pipeline.
Chronic Heart Failure Epidemiology
Heart failure (HF) is a rapidly growing public health issue affecting approximately 64 million people globally. In the United States, 6.7 million adults are affected, with projections rising to 8.7 million by 2030. In the United Kingdom, 1 million individuals live with HF while in Japan around 370,000 cases are expected by 2025. In India, HF prevalence is 1.2 per 1000 people. The chronic heart failure pipeline is expanding, focusing on innovative therapeutic products to address these escalating epidemiological challenges.
Chronic Heart Failure – Pipeline Therapeutic Assessment
This section of the report covers the analysis of chronic heart failure drug candidates based on several segmentations, including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Small Molecules
- Monoclonal Antibodies
- Peptides
- Gene Therapy
- RNA-based Therapies
- Others
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total chronic heart failure clinical trials.
The chronic heart disease pipeline is dominated by Phase II trials, representing approximately 33% of drugs under investigation. The remaining portfolio includes Phase IV at about 26%, Phase III at 21.69%, Phase I at 14.46%, and Early Phase I at 3.61%. This distribution demonstrates a strategic focus on mid-to-late clinical development, reflecting robust progress toward innovative therapies.
Chronic Heart Failure – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the chronic heart failure pipeline analysis include small molecules, monoclonal antibodies, peptides, gene therapy, RNA-based therapies, and others. The chronic heart failure report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for chronic heart failure.
Small molecule-based ERBB4 agonists are emerging as promising candidates for chronic heart failure treatment. For instance, EF-1, a potent small molecule, effectively induces ERBB4 dimerization, reducing cardiomyocyte cell death, hypertrophy, and fibrosis. This approach offers potential advantages over recombinant proteins, possibly revolutionizing heart failure management through enhanced cardioprotective and anti-fibrotic effects.
Chronic Heart Failure Clinical Trials – Key Players
The EMR report for the chronic heart failure drug pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed chronic heart failure therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in chronic heart failure clinical trials:
- AstraZeneca
- Help Therapeutics
- Akros Pharma Inc.
- Zensun Sci. & Tech. Co., Ltd.
- Tasly Pharmaceutical Group Co., Ltd.
- Viatris Inc.
- Cytokinetics
- Cardurion Pharmaceuticals, Inc.
- Salubris Biotherapeutics Inc.
- CALYX Inc.
- Merck Sharp & Dohme LLC
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for chronic heart failure. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of chronic heart failure drug candidates.
Drug: rhNRG-1
rhNRG-1, sponsored by Zensun Sci. & Tech. Co., Ltd., is a recombinant human neuregulin-1β designed to restore cardiomyocyte structure and function in chronic heart failure (CHF). It is a part of a Phase III study, which is evaluating its efficacy in reducing mortality in CHF patients with NT-proBNP levels between 600-1700 pg/mL and NYHA class II-III. rhNRG-1 activates ErbB2/ErbB4 receptors, inhibiting apoptosis and reversing left ventricular remodeling. Preclinical and clinical trials have shown promising results in enhancing heart function and reducing all-cause mortality. The study, enrolling 1,600 participants, is expected to be completed by February 2026.
Drug: AZD5462
AZD5462, developed by AstraZeneca, is currently undergoing a Phase II study to evaluate its effects on cardiac function in chronic heart failure (CHF) patients. The study is examining the drug’s efficacy, safety, and pharmacokinetics. AZD5462 is an oral RXFP1 agonist, designed to activate relaxin-2 receptors, improving vascular function and reducing fibrosis. By enhancing cardiac output and lowering vascular resistance, it aims to optimize organ perfusion. AZD5462’s innovative mechanism positions it as a promising chronic heart failure therapeutic product with potential long-term benefits.
Drug: JK07
JK07, developed by Salubris Biotherapeutics Inc., is currently being evaluated in a Phase II study to assess its safety, tolerability, and efficacy in chronic heart failure patients. This recombinant antibody fusion protein targets the ErbB3 receptor while selectively stimulating ErbB4, enhancing heart regeneration. By improving the therapeutic window of neuregulin-1 (NRG-1), JK07 aims to deliver better clinical outcomes with fewer side effects.
Key Questions Answered in the Chronic Heart Failure – Pipeline Insight Report
- Which companies/institutions are leading the chronic heart failure drug development?
- What is the efficacy and safety profile of chronic heart failure pipeline drugs?
- Which company is leading the chronic heart failure pipeline development activities?
- What is the current chronic heart failure commercial assessment?
- What are the opportunities and challenges present in the chronic heart failure pipeline landscape?
- What is the efficacy and safety profile of chronic heart failure pipeline drugs?
- Which company is conducting major trials for chronic heart failure drugs?
- Which companies/institutions are involved in chronic heart failure collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in chronic heart failure?
The Chronic Heart Failure Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for chronic heart failure. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into chronic heart failure collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Congestive Heart Failure (CHF) Epidemiology Forecast
Global Heart Health Supplements Market Report and Forecast
Global Clinical Trials Market
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Chronic Heart Failure
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Chronic Heart Failure
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Chronic Heart Failure: Epidemiology Snapshot
- 5.1 Chronic Heart Failure Incidence by Key Markets
- 5.2 Chronic Heart Failure – Patients Seeking Treatment in Key Markets
- 6 Chronic Heart Failure: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Chronic Heart Failure: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Chronic Heart Failure, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Chronic Heart Failure Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Chronic Heart Failure Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: rhNRG-1
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Drug: Omecamtiv Mecarbil (OM)
- 10.2.3 Other Drugs
- 11 Chronic Heart Failure Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: AZD5462
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: Ertugliflozin
- 11.2.3 Drug: Tovinontrine (CRD-750)
- 11.2.4 Drug: JK07
- 11.2.5 Other Drugs
- 12 Chronic Heart Failure Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Biological: Human (Allogeneic) iPS-Cell-Derived Cardiomyocyte
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Chronic Heart Failure Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Chronic Heart Failure, Key Drug Pipeline Companies
- 14.1 AstraZeneca
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Help Therapeutics
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Akros Pharma Inc.
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Zensun Sci. & Tech. Co., Ltd.
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Tasly Pharmaceutical Group Co., Ltd.
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Viatris Inc.
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Cytokinetics
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Cardurion Pharmaceuticals, Inc.
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 14.9 Salubris Biotherapeutics Inc.
- 14.9.1 Company Snapshot
- 14.9.2 Pipeline Product Portfolio
- 14.9.3 Financial Analysis
- 14.9.4 Recent News and Developments
- 14.10 CALYX Inc.
- 14.10.1 Company Snapshot
- 14.10.2 Pipeline Product Portfolio
- 14.10.3 Financial Analysis
- 14.10.4 Recent News and Developments
- 14.11 Merck Sharp & Dohme LLC
- 14.11.1 Company Snapshot
- 14.11.2 Pipeline Product Portfolio
- 14.11.3 Financial Analysis
- 14.11.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook